
|
Important Information: 1. The Strategic Investment Services (“SIS”) is an umbrella fund which has within it different Sub-Funds investing primarily in equities, property securities, fixed income securities and other collective investment schemes, each with a different risk profile. |
The SIS Defensive Growth Fund, SIS Growth Fund, SIS High Growth Fund, SIS US Dollar Fund, SIS International Fixed Interest Fund, SIS International Equity Fund, SIS International Property Securities Fund and SIS Asia Pacific ex-Japan Equity Fund are part of a product offering called the Strategic Investment Service. The issuer of this website is ipac financial planning
The website has not been reviewed by Hong Kong Securities and Futures Commission and Monetary Authority of Singapore.
This information on the following pages has been prepared to provide general information only; it is not intended to be a formal research report nor to take the place of professional advice. The information expressed herein is current as at the date of this publication and does not constitute an offer, recommendation or solicitation, nor does it constitute any prediction of likely future fund performance. Investors should seek advice from a licensed professional. The Prospectus, Singapore Statement and Hong Kong Covering Document are available and you should read the Prospectus, and Singapore Statement/Hong Kong Covering Document for further details including product features and risk factors before making a decision about whether to invest in the Strategic Investment Service.
Please note that the investment involves risk and the value of the units in the scheme and the income accruing to units may fall or rise. Past performance information presented is not indicative of future performance. Performance is calculated using the month-end sell price and is net of management fees. Distributions are reinvested. Market exposure and returns are sourced from ipac investment services.
Hong Kong Securities and Futures Commission or Monetary Authority of Singapore authorization is not a recommendation or endorsement of a product nor does it guarantee the commercial merits of a product or its performance. It does not mean the product is suitable for all investors nor is it an endorsement of its suitability for any particular investor or class of investors.